All In MedTech

FDA Clearance Tracker · P010055-S007

PROSTALUND CORETHERM SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 29, 2014 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 29, 2014

Approved

Time to decision

1,603 days

Received Sep 9, 2009. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P010055-S007
Device name
PROSTALUND CORETHERM SYSTEM
Applicant
Prostalund AB
Applicant location
Se-223 63 Lund
Received
Sep 9, 2009
Decided
Jan 29, 2014
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P010055

Device type

Device class
Class III

Every decision under product code MEQ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR MODIFICATION OF THE INDICATIONS FOR USE AND ASSOCIATED MODIFICATIONS TO THE CATHETER, ANTENNA, AND TEMPERATURE PROBE FOR PATIENTS WITH PROSTATES SMALLER THAN CURRENTLY INDICATED. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME CORETHERMACCESSORIES FOR SMALL PROSTATES AND IS INDICATED FOR USE TOGETHER WITH PROSTALUND CORETHERM /SE IN PATIENTS WITH GLANDS SIZE 20-50G AND WITH A PROSTATE LENGTH ¿25 MM.

Source documents

Other decisions for Prostalund AB

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.